SCHEMBL16065335

SCHEMBL16065335

C/C=C/c1cc(Nc2cc(Cl)nc(SC)n2)n[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ GAA P10253 1/20 0.49
▸ AURKA O14965 4/20 0.40
▸ AURKB Q96GD4 4/20 0.40
▸ PIK3C3 Q8NEB9 3/20 0.33
▸ GSK3B P49841 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ IGF1R P08069 2/20 0.33
▸ DAPK3 O43293 1/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ PAK4 O96013 1/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ LCK P06239 1/20 0.32
▸ FYN P06241 1/20 0.32
▸ CSF1R P07333 1/20 0.32
▸ RET P07949 1/20 0.32
▸ PDGFRB P09619 1/20 0.32
▸ FGFR1 P11362 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12102876 0.82 MEN1 (0.52) KMT2AMEN1SMN1; SMN2GAAAURKA
SCHEMBL15704951 0.79 AURKA (0.41) KMT2AMEN1AURKAAURKBPIK3C3
SCHEMBL15667867 0.79 AURKA (0.41) KMT2AMEN1AURKAAURKBPIK3C3
SCHEMBL15704900 0.76 IGF1R (0.52) KMT2AMEN1SMN1; SMN2GAAPIK3C3
SCHEMBL61333 0.73 KMT2A (0.53) KMT2AMEN1SMN1; SMN2GAAAURKA
SCHEMBL2614898 0.69 KMT2A (0.57) KMT2AMEN1SMN1; SMN2GAAAURKA
SCHEMBL3079698 0.68 KMT2A (0.56) KMT2AMEN1SMN1; SMN2GAAAURKA
SCHEMBL2090416 0.68 MEN1 (0.73) KMT2AMEN1SMN1; SMN2GAAPPARA
SCHEMBL31073526 0.68 KMT2A (0.56) KMT2AMEN1SMN1; SMN2GAAAURKA
SCHEMBL31073527 0.68 KMT2A (0.56) KMT2AMEN1SMN1; SMN2GAAAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10245261-B2 Substituted indol-5-ol derivatives and their therapeutic applications NANTBIO, INC. (US) 2019-04-02 — — US disclosed
US-20170189400-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. 2017-07-06 — — US disclosed
US-20170189400-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. 2017-07-06 — — US disclosed
US-20170088544-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIO, INC. 2017-03-30 — — US disclosed
US-20170088544-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIO, INC. 2017-03-30 — — US disclosed
US-9550760-B2 Substituted indol-5-ol derivatives and their therapeutic applications NANTBIOSCIENCE, INC. (US) 2017-01-24 — — US disclosed
US-9550760-B2 Substituted indol-5-ol derivatives and their therapeutic applications NANTBIOSCIENCE, INC. (US) 2017-01-24 — — US disclosed
US-9458137-B2 Substituted indol-5-ol derivatives and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2016-10-04 — — US disclosed
US-9458137-B2 Substituted indol-5-ol derivatives and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2016-10-04 — — US disclosed
US-20160016945-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. 2016-01-21 — — US disclosed
US-20160016945-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. 2016-01-21 — — US disclosed
US-20150291564-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. (US) 2015-10-15 — — US disclosed
US-20150291564-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. (US) 2015-10-15 — — US disclosed
WO-2014145403-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS NANTBIO, INC. (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189400-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS GRK5, GRK3, CDK5 KMT2A 2312/4885MEN1 3843/4885SMN1; SMN2 2712/4885
US-20170088544-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS GRK5, GRK3, MTMR1 KMT2A 2339/4885MEN1 4003/4885SMN1; SMN2 2690/4885
US-10245261-B2 Substituted indol-5-ol derivatives and their therapeutic applications GRK5, GRK3, CDK5 KMT2A 2312/4885MEN1 3843/4885SMN1; SMN2 2712/4885
US-20150291564-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS GRK5, GRK3, MTMR1 KMT2A 2339/4885MEN1 4003/4885SMN1; SMN2 2690/4885
US-20160016945-A1 SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS GRK5, GRK3, CDK5 KMT2A 2312/4885MEN1 3843/4885SMN1; SMN2 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback